Market Currents

• Monday, April 20, 2009

• 15:34 PM Unlike many pharmaceutical deals, which often deliver little, if any, value as anticipated new treatments fail to materialize, Glaxo's (GSX) Stiefel acquisition looks likely to make money for shareholders. GSK -1.7%. Comment!

• Monday, August 4, 2008

• 16:37 PM Gasco Energy (GSX): Q2 EPS of $0.03 in-line. Revenue of $12.6M (+147.1%) vs. $11.8M. [PR] Comment!